Symptomatic treatment of multiple sclerosis

被引:103
|
作者
Henze, T.
Rieckmann, P.
Toyka, K. V.
机构
[1] Reha Zentrum Nittenau, Rehabil Zentrum Neurol, DE-93149 Nittenau, Germany
[2] Univ Wurzburg, Dept Neurol, D-8700 Wurzburg, Germany
关键词
multiple sclerosis; symptomatic treatment; consensus guidelines; expert opinion; evidence-based medicine;
D O I
10.1159/000095699
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different drugs are used for the treatment of MS symptoms, but only a few of them have been investigated, especially in MS patients, and are approved by the national health authorities. Despite an overwhelming number of publications, only a few evidence-based studies exist and consensus reports are very rare, too. Therefore, it seemed necessary to develop a consensus statement on symptomatic treatment of MS comprising existing evidence-based literature as well as therapeutic experience of neurologists who have dealt with these problems over a long time. This consensus paper contains proposals for the treatment of the most common MS symptoms: disorders of motor function and coordination, of cranial nerve function, of autonomic, cognitive, and psychological functions as well as MS-related pain syndromes and epileptic seizures. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:78 / 105
页数:28
相关论文
共 50 条
  • [31] Cannabinoids in Symptomatic Treatment for People with Multiple Sclerosis: a Systematic Review of Randomised Studies
    Graziella Filippini
    Silvia Minozzi
    Francesca Borrelli
    Michela Cinquini
    Kerry Dwan
    Current Physical Medicine and Rehabilitation Reports, 2023, 11 : 303 - 312
  • [32] Quantification of the usage of symptomatic treatment in patients suffering from multiple sclerosis.
    Hernandez Valero, Erelido
    Benet Rodriguez, Mikhail
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2007, 5 (02): : 3 - 13
  • [33] Cannabinoids in Symptomatic Treatment for People with Multiple Sclerosis: a Systematic Review of Randomised Studies
    Filippini, Graziella
    Minozzi, Silvia
    Borrelli, Francesca
    Cinquini, Michela
    Dwan, Kerry
    CURRENT PHYSICAL MEDICINE AND REHABILITATION REPORTS, 2023, 11 (03) : 303 - 312
  • [34] Treatment of Multiple Sclerosis: A Review
    Hauser, Stephen L.
    Cree, Bruce A. C.
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (12) : 1380 - +
  • [35] Botulinum Toxin for Symptomatic Therapy in Multiple Sclerosis
    Michelle H. Cameron
    Francois Bethoux
    Nina Davis
    Meredith Frederick
    Current Neurology and Neuroscience Reports, 2014, 14
  • [36] Multiple Sclerosis in Pregnancy: A Commentary on Disease Modification and Symptomatic Drug Therapies
    Priyanka Iyer
    Ruth Dobson
    Neurology and Therapy, 2023, 12 : 1 - 10
  • [37] Multiple Sclerosis in Pregnancy: A Commentary on Disease Modification and Symptomatic Drug Therapies
    Iyer, Priyanka
    Dobson, Ruth
    NEUROLOGY AND THERAPY, 2023, 12 (01) : 1 - 10
  • [38] Botulinum Toxin for Symptomatic Therapy in Multiple Sclerosis
    Cameron, Michelle H.
    Bethoux, Francois
    Davis, Nina
    Frederick, Meredith
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2014, 14 (08)
  • [39] Potassium channel blockers in multiple sclerosis:: Neuronal KV channels and effects of symptomatic treatment
    Judge, Susan I. V.
    Bever, Christopher T., Jr.
    PHARMACOLOGY & THERAPEUTICS, 2006, 111 (01) : 224 - 259
  • [40] Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple Sclerosis
    Bruno, Antonio
    Annovazzi, Pietro
    Clerico, Marinella
    Cocco, Eleonora
    Conte, Antonella
    Marfia, Girolama Alessandra
    Salvetti, Marco
    Tomassini, Valentina
    Clerici, Valentina Torri
    Totaro, Rocco
    Dolcetti, Ettore
    Centonze, Diego
    CURRENT NEUROPHARMACOLOGY, 2025, 23 (05) : 503 - 510